[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100569376":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":27,"centralContacts":31,"locations":39,"responsibleParty":62,"collaborators":10,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":10,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":10,"enrollmentInfo":74,"targetDuration":10,"studyType":77,"phases":10,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Henan Cancer Hospital","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental group",null,"PD-1 inhibitor combined therapy, 200mg, iv, q3w, 1 year for adjuvant therapy or 2 years for advanced therapy",[13],"Drug: PD-1 Inhibitors",{"label":15,"type":10,"description":16,"interventionNames":17},"Control group","PD-1 inhibitor mono-therapy, 200mg, iv, q3w, 1 year for adjuvant therapy or 2 years for advanced therapy",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","PD-1 Inhibitors","Patients received PD-1 inhibitors mono- or combined therapy in real-world clinical practice",[15,9],[25,26],"Nivolumab","Pembrolizumab",[28],{"name":29,"affiliation":5,"role":30},"Quanli Gao","STUDY_DIRECTOR",[32,37],{"name":33,"role":34,"phone":35,"phoneExt":10,"email":36},"Xiaomin Fu","CONTACT","+86037165587483","fuxiaomin0880@126.com",{"name":33,"role":34,"phone":35,"phoneExt":10,"email":38},"zlyygql0855@zzu.edu.cn",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital","RECRUITING","Zhengzhou","Henan","450008","China","CN",{"type":49,"coordinates":50},"Point",[51,52],113.64861,34.75778,{"lat":52,"lon":51},[55,59],{"name":56,"role":34,"phone":57,"phoneExt":10,"email":58},"Quanli Gao, Ph.D","+86-371-65587795","gaoquanli2015@126.com",{"name":60,"role":34,"phone":61,"phoneExt":10,"email":36},"Xiaomin Fu, Ph.D","+86-371-65587483",{"type":63,"investigatorFullName":29,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Chief of Immunotherapy department","100569376","the-immune-assessment-of-pd-1-antibody-therapy-in-tumor-100569376",false,"NCT06693440","The Immune Assessment of PD-1 Antibody Therapy in Tumor","The Immune Assessment of PD-1 Antibody Therapy in Tumor - A Case-Control Study","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Pathologically confirmed malignant tumors.\n3. Complete medical records.\n4. Assessable immune function test data.\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years.\n2. No confirmed tumor pathology.\n3. Untraceable medical records.\n4. Non-assessable immune function tests.","ALL","18 Years",{"count":75,"type":76},3000,"ESTIMATED","OBSERVATIONAL","This retrospective study will leverage previous immune function monitoring results in conjunction with clinical case data at this medical center.",[80,81],"Efficacy, Team","Adverse Event",[83,84,85],"PD(L)-1 inhibitor","efficacy","adverse event","2024-11-14",{"date":88,"type":89},"2024-11-18","ACTUAL",{"date":91,"type":89},"2021-07-01",{"date":93,"type":76},"2030-11-13",{"name":29,"class":6},1]